 | • レポートコード：MRC23Q35801 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、80ページ • 納品方法：Eメール（2-3日） • 産業分類：医薬品 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界の注意欠陥・多動性症候群治療市場について調査・分析し、世界の注意欠陥・多動性症候群治療市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（精神刺激薬、非精神刺激薬）、用途別セグメント分析（病院、薬局）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Pfizer Inc.、Eli Lilly and Company、Novartis AG、GlaxoSmithKline PLC、Mallinckrodt Pharmaceuticals、Hisamitsu Pharmaceutical Co., Inc.、Johnson & Johnson、UCB S.A.、Purdue Pharma L.P.などが含まれています。世界の注意欠陥・多動性症候群治療市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、注意欠陥・多動性症候群治療市場規模を推定する際に考慮しました。本レポートは、注意欠陥・多動性症候群治療の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、注意欠陥・多動性症候群治療に関するビジネス上の意思決定に役立てることを目的としています。 ・注意欠陥・多動性症候群治療市場の概要 - 注意欠陥・多動性症候群治療のタイプ別セグメント - 世界の注意欠陥・多動性症候群治療市場規模：タイプ別分析（精神刺激薬、非精神刺激薬） - 注意欠陥・多動性症候群治療の用途別セグメント - 世界の注意欠陥・多動性症候群治療市場規模：用途別分析（病院、薬局） - 世界の注意欠陥・多動性症候群治療市場規模予測（2018年-2029年） ・注意欠陥・多動性症候群治療市場の成長トレンド - 注意欠陥・多動性症候群治療の地域別市場規模（2018年-2029年） - 注意欠陥・多動性症候群治療市場ダイナミクス - 注意欠陥・多動性症候群治療の業界動向 - 注意欠陥・多動性症候群治療市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：精神刺激薬、非精神刺激薬 - 世界の注意欠陥・多動性症候群治療のタイプ別市場規模（2018年-2023年） - 世界の注意欠陥・多動性症候群治療のタイプ別市場規模（2024年-2029年） ・用途別セグメント：病院、薬局 - 世界の注意欠陥・多動性症候群治療の用途別市場規模（2018年-2023年） - 世界の注意欠陥・多動性症候群治療の用途別市場規模（2024年-2029年） ・注意欠陥・多動性症候群治療の地域別市場規模 - 北米の注意欠陥・多動性症候群治療市場規模（2018年-2029年） - アメリカの注意欠陥・多動性症候群治療市場規模（2018年-2029年） - ヨーロッパの注意欠陥・多動性症候群治療市場規模（2018年-2029年） - アジア太平洋の注意欠陥・多動性症候群治療市場規模（2018年-2029年） - 中国の注意欠陥・多動性症候群治療市場規模（2018年-2029年） - 日本の注意欠陥・多動性症候群治療市場規模（2018年-2029年） - 韓国の注意欠陥・多動性症候群治療市場規模（2018年-2029年） - インドの注意欠陥・多動性症候群治療市場規模（2018年-2029年） - オーストラリアの注意欠陥・多動性症候群治療市場規模（2018年-2029年） - 中南米の注意欠陥・多動性症候群治療市場規模（2018年-2029年） - 中東・アフリカの注意欠陥・多動性症候群治療市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Pfizer Inc.、Eli Lilly and Company、Novartis AG、GlaxoSmithKline PLC、Mallinckrodt Pharmaceuticals、Hisamitsu Pharmaceutical Co., Inc.、Johnson & Johnson、UCB S.A.、Purdue Pharma L.P. ・アナリストの観点/結論 ・調査方法とデータソース |
Highlights
The global Attention Deficit Hyperactivity Syndrome Treatment market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Attention Deficit Hyperactivity Syndrome Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Attention Deficit Hyperactivity Syndrome Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Attention Deficit Hyperactivity Syndrome Treatment in Hospital is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Attention Deficit Hyperactivity Syndrome Treatment include Pfizer Inc., Eli Lilly and Company, Novartis AG, GlaxoSmithKline PLC, Mallinckrodt Pharmaceuticals, Hisamitsu Pharmaceutical Co., Inc., Johnson & Johnson, UCB S.A. and Purdue Pharma L.P., etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Attention Deficit Hyperactivity Syndrome Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Attention Deficit Hyperactivity Syndrome Treatment.
The Attention Deficit Hyperactivity Syndrome Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Attention Deficit Hyperactivity Syndrome Treatment market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Attention Deficit Hyperactivity Syndrome Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Pfizer Inc.
Eli Lilly and Company
Novartis AG
GlaxoSmithKline PLC
Mallinckrodt Pharmaceuticals
Hisamitsu Pharmaceutical Co., Inc.
Johnson & Johnson
UCB S.A.
Purdue Pharma L.P.
Segment by Type
Stimulant Drugs
Non-Stimulant Drugs
Segment by Application
Hospital
Retail Pharmacy
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Attention Deficit Hyperactivity Syndrome Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Attention Deficit Hyperactivity Syndrome Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Stimulant Drugs
1.2.3 Non-Stimulant Drugs
1.3 Market by Application
1.3.1 Global Attention Deficit Hyperactivity Syndrome Treatment Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Attention Deficit Hyperactivity Syndrome Treatment Market Perspective (2018-2029)
2.2 Attention Deficit Hyperactivity Syndrome Treatment Growth Trends by Region
2.2.1 Global Attention Deficit Hyperactivity Syndrome Treatment Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Attention Deficit Hyperactivity Syndrome Treatment Historic Market Size by Region (2018-2023)
2.2.3 Attention Deficit Hyperactivity Syndrome Treatment Forecasted Market Size by Region (2024-2029)
2.3 Attention Deficit Hyperactivity Syndrome Treatment Market Dynamics
2.3.1 Attention Deficit Hyperactivity Syndrome Treatment Industry Trends
2.3.2 Attention Deficit Hyperactivity Syndrome Treatment Market Drivers
2.3.3 Attention Deficit Hyperactivity Syndrome Treatment Market Challenges
2.3.4 Attention Deficit Hyperactivity Syndrome Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Attention Deficit Hyperactivity Syndrome Treatment Players by Revenue
3.1.1 Global Top Attention Deficit Hyperactivity Syndrome Treatment Players by Revenue (2018-2023)
3.1.2 Global Attention Deficit Hyperactivity Syndrome Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Attention Deficit Hyperactivity Syndrome Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Attention Deficit Hyperactivity Syndrome Treatment Revenue
3.4 Global Attention Deficit Hyperactivity Syndrome Treatment Market Concentration Ratio
3.4.1 Global Attention Deficit Hyperactivity Syndrome Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Attention Deficit Hyperactivity Syndrome Treatment Revenue in 2022
3.5 Attention Deficit Hyperactivity Syndrome Treatment Key Players Head office and Area Served
3.6 Key Players Attention Deficit Hyperactivity Syndrome Treatment Product Solution and Service
3.7 Date of Enter into Attention Deficit Hyperactivity Syndrome Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Attention Deficit Hyperactivity Syndrome Treatment Breakdown Data by Type
4.1 Global Attention Deficit Hyperactivity Syndrome Treatment Historic Market Size by Type (2018-2023)
4.2 Global Attention Deficit Hyperactivity Syndrome Treatment Forecasted Market Size by Type (2024-2029)
5 Attention Deficit Hyperactivity Syndrome Treatment Breakdown Data by Application
5.1 Global Attention Deficit Hyperactivity Syndrome Treatment Historic Market Size by Application (2018-2023)
5.2 Global Attention Deficit Hyperactivity Syndrome Treatment Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Attention Deficit Hyperactivity Syndrome Treatment Market Size (2018-2029)
6.2 North America Attention Deficit Hyperactivity Syndrome Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Attention Deficit Hyperactivity Syndrome Treatment Market Size by Country (2018-2023)
6.4 North America Attention Deficit Hyperactivity Syndrome Treatment Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Attention Deficit Hyperactivity Syndrome Treatment Market Size (2018-2029)
7.2 Europe Attention Deficit Hyperactivity Syndrome Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Attention Deficit Hyperactivity Syndrome Treatment Market Size by Country (2018-2023)
7.4 Europe Attention Deficit Hyperactivity Syndrome Treatment Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Attention Deficit Hyperactivity Syndrome Treatment Market Size (2018-2029)
8.2 Asia-Pacific Attention Deficit Hyperactivity Syndrome Treatment Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Attention Deficit Hyperactivity Syndrome Treatment Market Size by Region (2018-2023)
8.4 Asia-Pacific Attention Deficit Hyperactivity Syndrome Treatment Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Attention Deficit Hyperactivity Syndrome Treatment Market Size (2018-2029)
9.2 Latin America Attention Deficit Hyperactivity Syndrome Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Attention Deficit Hyperactivity Syndrome Treatment Market Size by Country (2018-2023)
9.4 Latin America Attention Deficit Hyperactivity Syndrome Treatment Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Attention Deficit Hyperactivity Syndrome Treatment Market Size (2018-2029)
10.2 Middle East & Africa Attention Deficit Hyperactivity Syndrome Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Attention Deficit Hyperactivity Syndrome Treatment Market Size by Country (2018-2023)
10.4 Middle East & Africa Attention Deficit Hyperactivity Syndrome Treatment Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer Inc.
11.1.1 Pfizer Inc. Company Detail
11.1.2 Pfizer Inc. Business Overview
11.1.3 Pfizer Inc. Attention Deficit Hyperactivity Syndrome Treatment Introduction
11.1.4 Pfizer Inc. Revenue in Attention Deficit Hyperactivity Syndrome Treatment Business (2018-2023)
11.1.5 Pfizer Inc. Recent Development
11.2 Eli Lilly and Company
11.2.1 Eli Lilly and Company Company Detail
11.2.2 Eli Lilly and Company Business Overview
11.2.3 Eli Lilly and Company Attention Deficit Hyperactivity Syndrome Treatment Introduction
11.2.4 Eli Lilly and Company Revenue in Attention Deficit Hyperactivity Syndrome Treatment Business (2018-2023)
11.2.5 Eli Lilly and Company Recent Development
11.3 Novartis AG
11.3.1 Novartis AG Company Detail
11.3.2 Novartis AG Business Overview
11.3.3 Novartis AG Attention Deficit Hyperactivity Syndrome Treatment Introduction
11.3.4 Novartis AG Revenue in Attention Deficit Hyperactivity Syndrome Treatment Business (2018-2023)
11.3.5 Novartis AG Recent Development
11.4 GlaxoSmithKline PLC
11.4.1 GlaxoSmithKline PLC Company Detail
11.4.2 GlaxoSmithKline PLC Business Overview
11.4.3 GlaxoSmithKline PLC Attention Deficit Hyperactivity Syndrome Treatment Introduction
11.4.4 GlaxoSmithKline PLC Revenue in Attention Deficit Hyperactivity Syndrome Treatment Business (2018-2023)
11.4.5 GlaxoSmithKline PLC Recent Development
11.5 Mallinckrodt Pharmaceuticals
11.5.1 Mallinckrodt Pharmaceuticals Company Detail
11.5.2 Mallinckrodt Pharmaceuticals Business Overview
11.5.3 Mallinckrodt Pharmaceuticals Attention Deficit Hyperactivity Syndrome Treatment Introduction
11.5.4 Mallinckrodt Pharmaceuticals Revenue in Attention Deficit Hyperactivity Syndrome Treatment Business (2018-2023)
11.5.5 Mallinckrodt Pharmaceuticals Recent Development
11.6 Hisamitsu Pharmaceutical Co., Inc.
11.6.1 Hisamitsu Pharmaceutical Co., Inc. Company Detail
11.6.2 Hisamitsu Pharmaceutical Co., Inc. Business Overview
11.6.3 Hisamitsu Pharmaceutical Co., Inc. Attention Deficit Hyperactivity Syndrome Treatment Introduction
11.6.4 Hisamitsu Pharmaceutical Co., Inc. Revenue in Attention Deficit Hyperactivity Syndrome Treatment Business (2018-2023)
11.6.5 Hisamitsu Pharmaceutical Co., Inc. Recent Development
11.7 Johnson & Johnson
11.7.1 Johnson & Johnson Company Detail
11.7.2 Johnson & Johnson Business Overview
11.7.3 Johnson & Johnson Attention Deficit Hyperactivity Syndrome Treatment Introduction
11.7.4 Johnson & Johnson Revenue in Attention Deficit Hyperactivity Syndrome Treatment Business (2018-2023)
11.7.5 Johnson & Johnson Recent Development
11.8 UCB S.A.
11.8.1 UCB S.A. Company Detail
11.8.2 UCB S.A. Business Overview
11.8.3 UCB S.A. Attention Deficit Hyperactivity Syndrome Treatment Introduction
11.8.4 UCB S.A. Revenue in Attention Deficit Hyperactivity Syndrome Treatment Business (2018-2023)
11.8.5 UCB S.A. Recent Development
11.9 Purdue Pharma L.P.
11.9.1 Purdue Pharma L.P. Company Detail
11.9.2 Purdue Pharma L.P. Business Overview
11.9.3 Purdue Pharma L.P. Attention Deficit Hyperactivity Syndrome Treatment Introduction
11.9.4 Purdue Pharma L.P. Revenue in Attention Deficit Hyperactivity Syndrome Treatment Business (2018-2023)
11.9.5 Purdue Pharma L.P. Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
